Unilever (NYSE: UL) boosts margins, spins off Ice Cream and launches €1.5B buyback
Unilever PLC delivered modest growth in 2025 while reshaping its portfolio through the demerger of Ice Cream and targeted deals. Underlying sales grew 3.5% with 1.5% volume and 2.0% price, while reported turnover fell 3.8% to €50.5 billion, mainly due to currency and disposals.
Profitability improved, with underlying operating margin up 60bps to 20.0% and gross margin rising to 46.9% as productivity savings and cost discipline offset inflation and FX. Underlying EPS increased to €3.08 and diluted EPS to €2.59. Free cash flow was strong at €5.9 billion with 100% cash conversion.
Unilever completed the Ice Cream demerger, retaining a 19.9% stake in The Magnum Ice Cream Company and recording a €3.4 billion gain from discontinued operations. It returned €6.0 billion to shareholders in 2025 via dividends and buybacks and approved a new share buyback of up to €1.5 billion, expected to start in the second quarter of 2026. Management expects 2026 underlying sales growth within a 4%–6% range, with at least 2% volume growth and a modest margin improvement versus 2025.
Positive
- Margin and cash strength: Underlying operating margin rose to 20.0% (up 60bps) and free cash flow reached €5.9 billion with 100% cash conversion, supporting a solid net debt/UEBITDA ratio of 2.0x.
- Strategic portfolio reset: Completion of the Ice Cream demerger, a €3.4 billion gain on demerger, and multiple focused acquisitions/divestitures sharpen exposure to higher-growth Beauty & Wellbeing and Personal Care.
- Shareholder returns: Unilever returned €6.0 billion in 2025 through dividends and buybacks and approved a new share buyback of up to €1.5 billion expected to commence in Q2 2026.
- Guided growth and margin uplift: Management targets 2026 underlying sales growth within a 4%–6% range, with at least 2% volume growth and a modest improvement in underlying operating margin versus 2025.
Negative
- None.
Insights
Unilever posts steady growth, stronger margins and a major portfolio reset.
Unilever delivered 2025 underlying sales growth of 3.5%, driven more by volume than price, while reported turnover declined to €50.5 billion because of FX and disposals. Mix increasingly favoured higher-growth Beauty & Wellbeing and Personal Care, both above 4% USG.
Margins moved higher despite currency headwinds. Underlying operating margin reached 20.0%, up 60bps, helped by a productivity programme that has already delivered about €670 million of savings toward a targeted €800 million. Free cash flow of €5.9 billion and net debt/UEBITDA of 2.0x support balance-sheet resilience.
The completed Ice Cream demerger and subsequent listing of TMICC simplified the group and generated a €3.4 billion gain in discontinued operations. Alongside portfolio bolt‑ons like Dr. Squatch and Minimalist, Unilever also returned €6.0 billion to shareholders and plans a new €1.5 billion buyback in 2026. Management guides to 4%–6% underlying sales growth and modest margin improvement in 2026, albeit at the lower end of the range given slower markets.
FAQ
How did Unilever (UL) perform financially in 2025?
What is Unilever’s 2026 outlook for growth and margins?
What happened with Unilever’s Ice Cream business and TMICC?
How strong was Unilever’s cash flow and balance sheet in 2025?
What shareholder returns did Unilever (UL) provide and plan?
How did Unilever’s main business groups perform in 2025?
What progress did Unilever make on its productivity programme?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
Underlying performance
|
|
|
GAAP measures
|
||||
|
(unaudited)
|
2025
|
vs 2024(b)
|
|
|
|
2025
|
vs 2024(b)
|
|
Full Year
|
|
|
|
|
|
|
|
|
Underlying sales growth (USG)
|
|
3.5%
|
|
|
Turnover
|
50.5bn
|
(3.8)%
|
|
Beauty
& Wellbeing
|
|
4.3%
|
|
|
Beauty
& Wellbeing
|
€12.8bn
|
(2.3)%
|
|
Personal
Care
|
|
4.7%
|
|
|
Personal
Care
|
€13.2bn
|
(3.4)%
|
|
Home
Care
|
|
2.6%
|
|
|
Home
Care
|
€11.6bn
|
(6.4)%
|
|
Foods
|
|
2.5%
|
|
|
Foods
|
€12.9bn
|
(3.2)%
|
|
Underlying operating profit
|
€10.1bn
|
(1.1%)
|
|
|
Operating profit
|
€9.0bn
|
2.4%
|
|
Underlying operating margin
|
20.0%
|
60bps
|
|
|
Operating margin
|
17.9%
|
110bps
|
|
Underlying earnings per share
|
€3.08
|
0.7%
|
|
|
Diluted earnings per share
|
€2.59
|
6.2%
|
|
Free cash flow
|
€5.9bn
|
€(0.4)bn
|
|
|
Net profit
|
€6.2bn
|
2.9%
|
|
Fourth Quarter
|
|
|
|
|
|
|
|
|
USG
|
|
4.2%
|
|
|
Turnover
|
€12.6bn
|
(2.7)%
|
|
Quarterly dividend payable in March
2026 (a)
|
|
|
€0.4664
|
per share(b)
|
|||
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
A&D
|
Currency
|
Turnover change
|
|
Full Year
|
€50.5bn
|
3.5%
|
1.5%
|
2.0%
|
(1.2)%
|
(5.9)%
|
(3.8)%
|
|
Fourth
Quarter
|
€12.6bn
|
4.2%
|
2.1%
|
2.0%
|
1.0%
|
(7.5)%
|
(2.7)%
|
|
(unaudited)
|
UOP
|
UOP growth
|
UOM%
|
Change in UOM
|
OP
|
OP growth
|
OM%
|
Change in OM
|
|
Full Year
|
€10.1bn
|
(1.1)%
|
20.0%
|
60bps
|
€9.0bn
|
2.4%
|
17.9%
|
110bps
|
|
Date
|
Events
|
|
17 February 2026
|
CAGNY Conference 2026
|
|
30 April 2026
|
Q1 2026 Trading Statement
|
|
|
Full Year 2025
|
Fourth Quarter 2025
|
||||||||
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
UOM
|
Change in UOM
|
Turnover
|
USG
|
UVG
|
UPG
|
|
Unilever
|
€50.5bn
|
3.5%
|
1.5%
|
2.0%
|
20.0%
|
60bps
|
€12.6bn
|
4.2%
|
2.1%
|
2.0%
|
|
Beauty & Wellbeing
|
€12.8bn
|
4.3%
|
2.2%
|
2.1%
|
19.2%
|
(20)bps
|
€3.2bn
|
4.7%
|
2.8%
|
1.8%
|
|
Personal Care
|
€13.2bn
|
4.7%
|
1.1%
|
3.6%
|
22.6%
|
50bps
|
€3.3bn
|
5.1%
|
0.6%
|
4.5%
|
|
Home Care
|
€11.6bn
|
2.6%
|
2.2%
|
0.4%
|
14.9%
|
40bps
|
€2.8bn
|
4.7%
|
4.0%
|
0.6%
|
|
Foods
|
€12.9bn
|
2.5%
|
0.8%
|
1.7%
|
22.6%
|
130bps
|
€3.3bn
|
2.3%
|
1.3%
|
1.0%
|
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
A&D
|
Currency
|
Turnover change
|
UOM%
|
Change in UOM
|
|
Full Year
|
€12.8bn
|
4.3%
|
2.2%
|
2.1%
|
(0.6)%
|
(5.8)%
|
(2.3)%
|
19.2%
|
(20)bps
|
|
Fourth Quarter
|
€3.2bn
|
4.7%
|
2.8%
|
1.8%
|
0.5%
|
(8.4)%
|
(3.7)%
|
|
|
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
A&D
|
Currency
|
Turnover change
|
UOM%
|
Change in UOM
|
|
Full Year
|
€13.2bn
|
4.7%
|
1.1%
|
3.6%
|
(1.8)%
|
(6.0)%
|
(3.4)%
|
22.6%
|
50bps
|
|
Fourth Quarter
|
€3.3bn
|
5.1%
|
0.6%
|
4.5%
|
4.7%
|
(7.1)%
|
2.2%
|
|
|
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
A&D
|
Currency
|
Turnover change
|
UOM%
|
Change in UOM
|
|
Full Year
|
€11.6bn
|
2.6%
|
2.2%
|
0.4%
|
(1.7)%
|
(7.1)%
|
(6.4)%
|
14.9%
|
40bps
|
|
Fourth Quarter
|
€2.8bn
|
4.7%
|
4.0%
|
0.6%
|
(0.2)%
|
(8.5)%
|
(4.4)%
|
|
|
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
A&D
|
Currency
|
Turnover change
|
UOM%
|
Change in UOM
|
|
Full Year
|
€12.9bn
|
2.5%
|
0.8%
|
1.7%
|
(0.8)%
|
(4.7)%
|
(3.2)%
|
22.6%
|
130bps
|
|
Fourth Quarter
|
€3.3bn
|
2.3%
|
1.3%
|
1.0%
|
(1.2)%
|
(6.1)%
|
(5.1)%
|
|
|
|
|
Full Year 2025
|
Fourth Quarter 2025
|
||||||
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
Turnover
|
USG
|
UVG
|
UPG
|
|
Unilever
|
€50.5bn
|
3.5%
|
1.5%
|
2.0%
|
€12.6bn
|
4.2%
|
2.1%
|
2.0%
|
|
Asia Pacific Africa
|
€22.4bn
|
4.6%
|
3.0%
|
1.6%
|
€5.5bn
|
6.9%
|
5.7%
|
1.2%
|
|
The Americas
|
€18.6bn
|
3.3%
|
-%
|
3.2%
|
€4.7bn
|
3.0%
|
(0.8)%
|
3.8%
|
|
Europe
|
€9.5bn
|
1.5%
|
1.2%
|
0.3%
|
€2.4bn
|
0.1%
|
(0.2)%
|
0.3%
|
|
|
Full Year 2025
|
Fourth Quarter 2025
|
||||||
|
(unaudited)
|
Turnover
|
USG
|
UVG
|
UPG
|
Turnover
|
USG
|
UVG
|
UPG
|
|
Emerging markets
|
€30.0bn
|
3.5%
|
0.8%
|
2.7%
|
€7.4bn
|
5.8%
|
3.2%
|
2.5%
|
|
Developed markets
|
€20.5bn
|
3.6%
|
2.6%
|
0.9%
|
€5.2bn
|
1.7%
|
0.5%
|
1.1%
|
|
North America
|
€11.2bn
|
5.3%
|
3.8%
|
1.4%
|
€2.8bn
|
2.8%
|
1.3%
|
1.5%
|
|
Latin America
|
€7.4bn
|
0.5%
|
(5.1)%
|
5.9%
|
€1.9bn
|
3.2%
|
(3.6)%
|
7.1%
|
|
|
Annual average
rate in 2025
|
Annual average
rate in 2024
|
|
Brazilian real (€1 = BRL)
|
6.297
|
5.761
|
|
Chinese yuan (€1 = CNY)
|
8.092
|
7.751
|
|
Indian rupee (€1 = INR)
|
97.630
|
90.652
|
|
Indonesia rupiah (€1 = IDR)
|
18,481
|
17,177
|
|
Mexican peso (€1 = MXN)
|
21.710
|
19.589
|
|
Philippine peso (€1 = PHP)
|
64.488
|
62.055
|
|
Turkish lira (€1 = TRY)
|
49.277
|
36.671
|
|
UK pound sterling (€1 = GBP)
|
0.855
|
0.848
|
|
US dollar (€1 = US$)
|
1.124
|
1.085
|
|
(unaudited)
|
Beauty & Wellbeing
|
Personal Care
|
Home Care
|
Foods
|
Total
|
|
Fourth Quarter
|
|
|
|
|
|
|
Turnover (€ million)
|
|
|
|
|
|
|
2024
|
3,310
|
3,235
|
2,960
|
3,434
|
12,939
|
|
2025
|
3,189
|
3,307
|
2,830
|
3,260
|
12,586
|
|
Turnover growth (%)
|
(3.7)
|
2.2
|
(4.4)
|
(5.1)
|
(2.7)
|
|
Effect of acquisitions (%)
|
0.6
|
4.7
|
-
|
-
|
1.3
|
|
Effect of disposals (%)
|
(0.1)
|
-
|
(0.2)
|
(1.2)
|
(0.4)
|
|
Effect of currency-related items (%), of which:
|
(8.4)
|
(7.1)
|
(8.5)
|
(6.1)
|
(7.5)
|
|
Exchange rates changes (%)
|
(8.7)
|
(7.6)
|
(9.1)
|
(6.3)
|
(7.9)
|
|
Extreme price growth in hyperinflationary markets* (%)
|
0.4
|
0.5
|
0.7
|
0.3
|
0.5
|
|
Underlying sales growth (%)
|
4.7
|
5.1
|
4.7
|
2.3
|
4.2
|
|
Full Year
|
|
|
|
|
|
|
Turnover (€ million)
|
|
|
|
|
|
|
2024
|
13,157
|
13,618
|
12,352
|
13,352
|
52,479
|
|
2025
|
12,848
|
13,161
|
11,565
|
12,929
|
50,503
|
|
Turnover growth (%)
|
(2.3)
|
(3.4)
|
(6.4)
|
(3.2)
|
(3.8)
|
|
Effect of acquisitions (%)
|
0.4
|
1.9
|
-
|
-
|
0.6
|
|
Effect of disposals (%)
|
(1.0)
|
(3.6)
|
(1.7)
|
(0.8)
|
(1.8)
|
|
Effect of currency-related items (%), of which:
|
(5.8)
|
(6.0)
|
(7.1)
|
(4.7)
|
(5.9)
|
|
Exchange rates changes (%)
|
(6.2)
|
(6.5)
|
(7.7)
|
(5.1)
|
(6.3)
|
|
Extreme price growth in hyperinflationary markets* (%)
|
0.4
|
0.5
|
0.6
|
0.4
|
0.5
|
|
Underlying sales growth (%)
|
4.3
|
4.7
|
2.6
|
2.5
|
3.5
|
|
(unaudited)
|
Asia Pacific Africa
|
The Americas
|
Europe
|
Total
|
|
Fourth Quarter
|
|
|
|
|
|
Turnover (€ million)
|
|
|
|
|
|
2024
|
5,691
|
4,831
|
2,417
|
12,939
|
|
2025
|
5,497
|
4,707
|
2,382
|
12,586
|
|
Turnover growth (%)
|
(3.4)
|
(2.6)
|
(1.5)
|
(2.7)
|
|
Effect of acquisitions (%)
|
0.3
|
2.7
|
1.2
|
1.3
|
|
Effect of disposals (%)
|
-
|
(0.3)
|
(1.7)
|
(0.4)
|
|
Effect of currency-related items (%), of which:
|
(9.9)
|
(7.6)
|
(1.0)
|
(7.5)
|
|
Exchange rates changes (%)
|
(10.6)
|
(7.9)
|
(1.0)
|
(7.9)
|
|
Extreme price growth in hyperinflationary markets* (%)
|
0.7
|
0.3
|
-
|
0.5
|
|
Underlying sales growth (%)
|
6.9
|
3.0
|
0.1
|
4.2
|
|
Full Year
|
|
|
|
|
|
Turnover (€ million)
|
|
|
|
|
|
2024
|
23,448
|
19,605
|
9,426
|
52,479
|
|
2025
|
22,427
|
18,622
|
9,454
|
50,503
|
|
Turnover growth (%)
|
(4.4)
|
(5.0)
|
0.3
|
(3.8)
|
|
Effect of acquisitions (%)
|
0.2
|
0.9
|
0.9
|
0.6
|
|
Effect of disposals (%)
|
(2.4)
|
(1.1)
|
(1.9)
|
(1.8)
|
|
Effect of currency-related items (%), of which:
|
(6.5)
|
(7.8)
|
(0.1)
|
(5.9)
|
|
Exchange rates changes (%)
|
(7.0)
|
(8.4)
|
(0.1)
|
(6.3)
|
|
Extreme price growth in hyperinflationary markets* (%)
|
0.5
|
0.7
|
-
|
0.5
|
|
Underlying sales growth (%)
|
4.6
|
3.3
|
1.5
|
3.5
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(g)
|
|
Non-underlying items within operating profit before
tax
|
(1,047)
|
(1,369)
|
|
Acquisition and disposal-related
costs(a)
|
(288)
|
(293)
|
|
Gain on disposal of group
companies(b)
|
(36)
|
(229)
|
|
Restructuring costs(c)
|
(599)
|
(710)
|
|
Impairments(d)
|
(43)
|
(134)
|
|
Other(e)
|
(81)
|
(3)
|
|
Tax on non-underlying items within operating profit
|
7
|
88
|
|
Non-underlying items within operating profit after tax
|
(1,040)
|
(1,281)
|
|
Non-underlying items not in operating profit but within net profit
before tax
|
(34)
|
(167)
|
|
Interest related to non-underlying
items(f)
|
34
|
35
|
|
Net
monetary loss arising from hyperinflationary economies
|
(68)
|
(201)
|
|
Tax impact of non-underlying items not in operating profit but
within net profit, including non-underlying tax items
|
(39)
|
85
|
|
Non-underlying items not in operating profit but within net profit
after tax
|
(73)
|
(82)
|
|
Non-underlying items after tax
|
(1,113)
|
(1,363)
|
|
Attributable to:
|
|
|
|
Non-controlling
interests
|
(34)
|
22
|
|
Shareholders'
equity
|
(1,079)
|
(1,385)
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Operating profit
|
9,037
|
8,829
|
|
Non-underlying items within operating profit
|
1,047
|
1,369
|
|
Underlying operating profit
|
10,084
|
10,198
|
|
Turnover
|
50,503
|
52,479
|
|
Operating margin (%)
|
17.9
|
16.8
|
|
Underlying operating margin (%)
|
20.0
|
19.4
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Taxation
|
2,481
|
2,332
|
|
Tax impact of:
|
|
|
|
Non-underlying
items within operating profit
|
7
|
88
|
|
Non-underlying
items not in operating profit but within net profit
|
(39)
|
85
|
|
Taxation before tax impact of non-underlying items
|
2,449
|
2,505
|
|
Profit before taxation
|
8,693
|
8,371
|
|
Share of net profit of joint ventures and associates
|
(245)
|
(250)
|
|
Profit before tax excluding share of net profit of joint ventures
and associates
|
8,448
|
8,121
|
|
Non-underlying items within operating profit before
tax
|
1,047
|
1,369
|
|
Non-underlying items not in operating profit but within net profit
before tax
|
34
|
167
|
|
Profit before tax excluding non-underlying items before tax and
share of net profit of joint ventures and associates
|
9,529
|
9,657
|
|
Effective tax rate (%)
|
29.4
|
28.7
|
|
Underlying effective tax rate (%)
|
25.7
|
25.9
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Net profit
|
6,213
|
6,039
|
|
Non-controlling interest
|
(531)
|
(609)
|
|
Net profit attributable to shareholders' equity - used for basic
and diluted earnings per share
|
5,682
|
5,430
|
|
Post-tax impact of non-underlying items attributable to
shareholders' equity
|
1,079
|
1,385
|
|
Underlying profit attributable to shareholders' equity - used for
basic and diluted earnings per share
|
6,761
|
6,816
|
|
Diluted average number of shares (millions of share
units)
|
2,195
|
2,229
|
|
Diluted EPS (€)
|
2.59
|
2.44
|
|
Underlying EPS - diluted (€)
|
3.08
|
3.06
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024
|
|
Total financial liabilities
|
(28,278)
|
(32,053)
|
|
Current
financial liabilities
|
(2,582)
|
(6,987)
|
|
Non-current
financial liabilities
|
(25,696)
|
(25,066)
|
|
Cash and cash equivalents as per balance sheet
|
3,941
|
6,136
|
|
Cash
and cash equivalents as per cash flow statement
|
3,870
|
5,950
|
|
Add:
bank overdrafts deducted therein
|
65
|
180
|
|
Less:
cash and cash equivalents held for sale
|
6
|
6
|
|
Other current financial assets
|
1,121
|
1,330
|
|
Non-current financial asset derivatives that relate to financial
liabilities
|
140
|
68
|
|
Net debt
|
(23,076)
|
(24,519)
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Net profit from continuing operations
|
6,213
|
6,039
|
|
Net finance costs
|
503
|
520
|
|
Net monetary loss arising from hyperinflationary
economies
|
68
|
201
|
|
Share of net profit of joint ventures and associates
|
(245)
|
(250)
|
|
Other loss/(income) from non-current investments and
associates
|
17
|
(13)
|
|
Taxation
|
2,481
|
2,332
|
|
Operating profit
|
9,037
|
8,829
|
|
Depreciation and amortisation
|
1,310
|
1,236
|
|
Earnings before interest, taxes, depreciation and amortisation
(EBITDA)
|
10,347
|
10,065
|
|
Non-underlying items within operating profit
|
1,047
|
1,369
|
|
Underlying earnings before interest, taxes, depreciation and
amortisation (UEBITDA)
|
11,394
|
11,434
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Cash flow from operating activities
|
10,772
|
10,913
|
|
Income tax paid
|
(2,720)
|
(2,452)
|
|
Net capital expenditure
|
(1,465)
|
(1,599)
|
|
Net interest paid
|
(666)
|
(559)
|
|
Free cash flow
|
5,921
|
6,304
|
|
Net cash flow (used in)/from investing activities
|
(2,394)
|
(423)
|
|
Net cash flow used in financing activities
|
(9,884)
|
(6,829)
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Net profit
|
6,213
|
6,039
|
|
Loss/(gain) on disposal of group companies
|
36
|
229
|
|
Share of net profit of joint ventures and associates
|
(245)
|
(250)
|
|
Other (income)/loss from non-current investments and
associates
|
17
|
(13)
|
|
Tax on gain on disposal of group companies
|
239
|
140
|
|
Net profit excluding P&L on disposals, JV, associates,
NCI
|
6,260
|
6,145
|
|
Cash flow from operating activities
|
10,772
|
10,913
|
|
Free cash flow
|
5,921
|
6,304
|
|
Cash impact of tax on disposal
|
328
|
111
|
|
Free cash flow excluding cash impact of tax on
disposal
|
6,249
|
6,415
|
|
Cash conversion from operating activities (%)
|
173
|
181
|
|
Cash conversion (%)
|
100
|
104
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(c)
|
|
Operating profit
|
9,037
|
8,829
|
|
Tax on operating profit(a)
|
(2,657)
|
(2,534)
|
|
Operating profit after tax
|
6,380
|
6,295
|
|
|
|
|
|
Operating profit
|
9,037
|
8,829
|
|
Non-underlying items within operating profit
|
1,047
|
1,369
|
|
Underlying operating profit before tax
|
10,084
|
10,198
|
|
Tax on underlying operating profit(b)
|
(2,592)
|
(2,645)
|
|
Underlying operating profit after tax
|
7,492
|
7,553
|
|
Goodwill
|
17,709
|
22,311
|
|
Intangible assets
|
17,055
|
18,590
|
|
Property, plant and equipment
|
8,992
|
11,669
|
|
Net assets held for sale (d)
|
93
|
119
|
|
Inventories
|
4,043
|
5,177
|
|
Trade and other current receivables
|
7,346
|
6,011
|
|
Trade payables and other current liabilities
|
(16,939)
|
(16,690)
|
|
Period-end invested capital
|
38,298
|
47,187
|
|
Adjustment to 2024 period end balance for Ice Cream
demerger (e)
|
-
|
(6,481)
|
|
Adjusted period end invested capital
|
38,298
|
40,706
|
|
Average invested capital for the
period (f)
|
39,502
|
39,559
|
|
Return on invested capital (%)
|
16.2
|
15.9
|
|
Underlying return on invested capital (%)
|
19.0
|
19.1
|
|
UK
|
+44 77 4249 0136
|
press-office.london@unilever.com
|
investor.relations@unilever.com
|
|
|
or
|
+44 77 7999 9683
|
jonathan.sibun@teneo.com
|
|
|
|
NL
|
+31 63 029 6394
|
willemijn.storimans@unilever.com
|
|
|
|
or
|
+31 61 500 8293
|
fleur-van.bruggen@unilever.com
|
|
|
|
€ million
|
Full Year
|
||
|
(unaudited)
|
2025
|
2024(a)
|
Change
|
|
Turnover
|
50,503
|
52,479
|
(3.8)%
|
|
Operating profit
|
9,037
|
8,829
|
2.4%
|
|
Net finance costs
|
(503)
|
(520)
|
|
|
Pensions
and similar obligations
|
123
|
83
|
|
|
Finance
income
|
398
|
391
|
|
|
Finance
costs
|
(1,024)
|
(994)
|
|
|
Net monetary loss arising from hyperinflationary
economies
|
(68)
|
(201)
|
|
|
Share of net profit of joint ventures and associates
|
245
|
250
|
|
|
Other income/(loss) from non-current investments and
associates
|
(17)
|
13
|
|
|
Profit before taxation from continuing operations
|
8,693
|
8,371
|
3.9%
|
|
Taxation
|
(2,481)
|
(2,332)
|
|
|
Net profit from continuing operations
|
6,213
|
6,039
|
2.9%
|
|
Profit after taxation from discontinued operations
|
425
|
330
|
|
|
Gain on disposal of discontinued operation
|
3,373
|
-
|
|
|
Net profit from discontinued operations
|
3,798
|
330
|
|
|
Total net profit
|
10,011
|
6,369
|
|
|
|
|
|
|
|
Attributable to:
|
|
|
|
|
Non-controlling interests
|
542
|
625
|
|
|
Shareholders' equity
|
9,469
|
5,744
|
64.9%
|
|
Total profit attributable to shareholders' equity arises
from:
|
|
|
|
|
Continuing
operations
|
5,682
|
5,430
|
|
|
Discontinued
operations
|
3,787
|
314
|
|
|
Total profit attributable to non-controlling interests arises
from:
|
|
|
|
|
Continuing
operations
|
531
|
609
|
|
|
Discontinued
operations
|
11
|
16
|
|
|
Earnings per share
|
|
|
|
|
Basic earnings per share (euros)
|
4.33
|
2.59
|
67.0
%
|
|
Basic
earnings per share (€) from continuing
operations
|
2.60
|
2.45
|
6.1 %
|
|
Basic
earnings per share (€) from discontinued
operations
|
1.73
|
0.14
|
1124.3 %
|
|
Diluted earnings per share (euros)
|
4.32
|
2.58
|
67.6
%
|
|
Diluted
earnings per share (€) from continuing
operations
|
2.59
|
2.44
|
6.2 %
|
|
Diluted
earnings per share (€) from discontinued
operations
|
1.73
|
0.14
|
1125.1
%
|
|
€ million
|
Full Year
|
|
|
(unaudited)
|
2025
|
2024(a)
|
|
Net profit
|
10,011
|
6,369
|
|
Other comprehensive income from continuing operations
|
|
|
|
Items that will not be reclassified to profit or loss, net of
tax:
|
|
|
|
Gains/(losses)
on equity instruments measured at fair value through other
comprehensive income
|
(14)
|
60
|
|
Remeasurement
of defined benefit pension plans
|
137
|
226
|
|
Items that may be reclassified subsequently to profit or loss, net
of tax:
|
|
|
|
Gains/(losses)
on cash flow hedges
|
(111)
|
122
|
|
Currency
retranslation gains/(losses)
|
(2,239)
|
1,113
|
|
Total comprehensive income from continuing operations
|
(2,227)
|
1,521
|
|
Other comprehensive income from discontinued
operations
|
508
|
402
|
|
Total comprehensive income
|
8,292
|
8,292
|
|
|
|
|
|
Attributable to:
|
|
|
|
Non-controlling interests
|
187
|
712
|
|
Shareholders' equity
|
8,105
|
7,580
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
€ million
|
Called
up share
capital
|
Share
premium
account
|
Unification
reserve
|
Other
reserves
|
Retained
profit
|
Total
|
Non-
controlling
interest
|
Total
equity
|
|
1 January 2024
|
88
|
52,844
|
(73,364)
|
(8,518)
|
47,052
|
18,102
|
2,662
|
20,764
|
|
Profit or loss for the period
|
-
|
-
|
-
|
-
|
5,744
|
5,744
|
625
|
6,369
|
|
Other comprehensive income, net of tax:
|
|
|
|
|
|
|
|
|
|
Gains/(losses) on:
|
|
|
|
|
|
|
|
|
|
Equity
instruments gains/(losses)
|
-
|
-
|
-
|
60
|
-
|
60
|
-
|
60
|
|
Cash
flow hedges gains/(losses)
|
-
|
-
|
-
|
210
|
-
|
210
|
-
|
210
|
|
Remeasurements of defined benefit pension plans
|
-
|
-
|
-
|
-
|
269
|
269
|
(5)
|
264
|
|
Currency retranslation gains/(losses)(a)
|
-
|
-
|
-
|
406
|
891
|
1,297
|
92
|
1,389
|
|
Total comprehensive income
|
-
|
-
|
-
|
676
|
6,904
|
7,580
|
712
|
8,292
|
|
Dividends on ordinary capital
|
-
|
-
|
-
|
-
|
(4,320)
|
(4,320)
|
-
|
(4,320)
|
|
Repurchase of shares(d)
|
-
|
-
|
-
|
(1,508)
|
-
|
(1,508)
|
-
|
(1,508)
|
|
Movements in treasury shares(e)
|
-
|
-
|
-
|
25
|
(120)
|
(95)
|
-
|
(95)
|
|
Share-based payment credit(f)
|
-
|
-
|
-
|
-
|
324
|
324
|
-
|
324
|
|
Dividends paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
-
|
(712)
|
(712)
|
|
Hedging loss/(gain) transferred to non-financial
assets
|
-
|
-
|
-
|
(54)
|
-
|
(54)
|
-
|
(54)
|
|
Other movements in equity
|
-
|
-
|
-
|
80
|
(119)
|
(39)
|
(97)
|
(136)
|
|
31 December 2024
|
88
|
52,844
|
(73,364)
|
(9,299)
|
49,721
|
19,990
|
2,565
|
22,555
|
|
Profit or loss for the period
|
-
|
-
|
-
|
-
|
9,469
|
9,469
|
542
|
10,011
|
|
Other comprehensive income, net of tax:
|
|
|
|
|
|
|
|
|
|
Gains/(losses) on:
|
|
|
|
|
|
|
|
|
|
Equity
instruments (losses)/gains
|
-
|
-
|
-
|
(14)
|
-
|
(14)
|
-
|
(14)
|
|
Cash
flow hedges (losses)gains
|
-
|
-
|
-
|
(196)
|
-
|
(196)
|
(2)
|
(198)
|
|
Remeasurements of defined benefit pension plans
|
-
|
-
|
-
|
-
|
180
|
180
|
(4)
|
176
|
|
Currency retranslation (losses)/gains(a)
|
-
|
-
|
-
|
(1,258)
|
(76)
|
(1,334)
|
(349)
|
(1,683)
|
|
Total comprehensive income
|
-
|
-
|
-
|
(1,468)
|
9,573
|
8,105
|
187
|
8,292
|
|
Dividends on ordinary capital
|
-
|
-
|
-
|
-
|
(4,453)
|
(4,453)
|
-
|
(4,453)
|
|
Non-cash dividend to shareholders(b)
|
-
|
-
|
-
|
-
|
(6,752)
|
(6,752)
|
-
|
(6,752)
|
|
Cancellation of treasury shares(c)
|
(3)
|
-
|
-
|
3,770
|
(3,767)
|
-
|
-
|
-
|
|
Repurchase of shares(d)
|
-
|
-
|
-
|
(1,510)
|
-
|
(1,510)
|
-
|
(1,510)
|
|
Movements in treasury shares(e)
|
-
|
-
|
-
|
1
|
(152)
|
(151)
|
-
|
(151)
|
|
Share-based payment credit(f)
|
-
|
-
|
-
|
-
|
284
|
284
|
-
|
284
|
|
Dividends paid to non-controlling interests(g)
|
-
|
-
|
-
|
-
|
-
|
-
|
(728)
|
(728)
|
|
Hedging loss/(gain) transferred to non-financial
assets
|
-
|
-
|
-
|
(58)
|
-
|
(58)
|
1
|
(57)
|
|
Other movements in equity(h)
|
-
|
-
|
-
|
300
|
(225)
|
75
|
32
|
107
|
|
31 December 2025
|
85
|
52,844
|
(73,364)
|
(8,264)
|
44,229
|
15,530
|
2,057
|
17,587
|
|
(unaudited)
|
|
|
|
€ million
|
As at 31 December 2025
|
As at 31 December 2024
|
|
Non-current assets
|
|
|
|
Goodwill
|
17,709
|
22,311
|
|
Intangible assets
|
17,055
|
18,590
|
|
Property, plant and equipment
|
8,992
|
11,669
|
|
Pension asset for funded schemes in surplus
|
4,462
|
4,164
|
|
Deferred tax assets
|
1,146
|
1,280
|
|
Financial assets
|
3,065
|
1,571
|
|
Other non-current assets
|
976
|
971
|
|
|
53,405
|
60,556
|
|
Current assets
|
|
|
|
Inventories
|
4,043
|
5,177
|
|
Trade and other current receivables
|
7,346
|
6,011
|
|
Current tax assets
|
329
|
373
|
|
Cash and cash equivalents
|
3,941
|
6,136
|
|
Other financial assets
|
1,121
|
1,330
|
|
Assets held for sale
|
286
|
167
|
|
|
17,066
|
19,194
|
|
|
|
|
|
Total assets
|
70,471
|
79,750
|
|
|
|
|
|
Current liabilities
|
|
|
|
Financial liabilities
|
2,582
|
6,987
|
|
Trade payables and other current liabilities
|
16,939
|
16,690
|
|
Current tax liabilities
|
1,439
|
678
|
|
Provisions
|
589
|
831
|
|
Liabilities held for sale
|
113
|
48
|
|
|
21,662
|
25,234
|
|
Non-current liabilities
|
|
|
|
Financial liabilities
|
25,696
|
25,066
|
|
Non-current tax liabilities
|
303
|
585
|
|
Pensions and post-retirement healthcare liabilities:
|
|
|
|
Funded
schemes in deficit
|
100
|
173
|
|
Unfunded
schemes
|
844
|
1,021
|
|
Provisions
|
539
|
571
|
|
Deferred tax liabilities
|
3,603
|
4,342
|
|
Other non-current liabilities
|
137
|
203
|
|
|
31,222
|
31,961
|
|
|
|
|
|
Total liabilities
|
52,884
|
57,195
|
|
|
|
|
|
Equity
|
|
|
|
Shareholders' equity
|
15,530
|
19,990
|
|
Non-controlling interests
|
2,057
|
2,565
|
|
Total equity
|
17,587
|
22,555
|
|
|
|
|
|
Total liabilities and equity
|
70,471
|
79,750
|
|
(unaudited)
|
Full Year
|
|
|
€ million
|
2025
|
2024(a)
|
|
Net profit from continuing operations
|
6,213
|
6,039
|
|
Taxation
|
2,481
|
2,332
|
|
Share of net profit of joint ventures/associates and other
(income)/loss from non-current investments and
associates
|
(228)
|
(263)
|
|
Net monetary loss arising from hyperinflationary
economies
|
68
|
201
|
|
Net finance costs
|
503
|
520
|
|
Operating profit from continuing operations
|
9,037
|
8,829
|
|
Depreciation, amortisation and impairment
|
1,353
|
1,370
|
|
Changes in working capital
|
116
|
(188)
|
|
Inventories
|
(281)
|
(190)
|
|
Trade and other
receivables (b)
|
(2,620)
|
(211)
|
|
Trade payables and other
liabilities (b)
|
3,017
|
213
|
|
Pensions and similar obligations less payments
|
(74)
|
(54)
|
|
Provisions less payments
|
(130)
|
289
|
|
Elimination of loss/(profits) on disposals
|
58
|
259
|
|
Non-cash charge for share-based compensation
|
255
|
292
|
|
Other adjustments
|
157
|
116
|
|
Cash flow from continuing operating activities
|
10,772
|
10,913
|
|
Income tax paid on continuing operations
|
(2,720)
|
(2,452)
|
|
Net cash flow from continuing operating activities
|
8,052
|
8,461
|
|
Cash flow from operations attributable to discontinued
operations
|
475
|
1,231
|
|
Income tax paid from discontinued operation
|
(177)
|
(173)
|
|
Net cash flow from discontinued operating activities
|
298
|
1,058
|
|
Total cash flows from operating activities
|
8,350
|
9,519
|
|
Interest received
|
352
|
370
|
|
Purchase of intangible assets
|
(174)
|
(233)
|
|
Purchase of property, plant and equipment
|
(1,417)
|
(1,381)
|
|
Disposal of property, plant and equipment
|
126
|
15
|
|
Acquisition of businesses and investments in joint ventures and
associates
|
(1,674)
|
(734)
|
|
Disposal of businesses, joint ventures and associates
|
107
|
910
|
|
Acquisition of other non-current investments
|
(111)
|
(166)
|
|
Disposal of other non-current investments
|
239
|
59
|
|
Dividends from joint ventures, associates and other non-current
investments
|
243
|
261
|
|
Sale/(purchase) of financial assets
|
(85)
|
476
|
|
Net cash flow used in continuing investing activities
|
(2,394)
|
(423)
|
|
Net cash investing cash flows attributable to discontinued
operations
|
(724)
|
(202)
|
|
Total net cash (outflow)/inflow from investing
activities
|
(3,118)
|
(625)
|
|
Dividends paid on ordinary share capital
|
(4,453)
|
(4,319)
|
|
Interest paid
|
(1,018)
|
(929)
|
|
Net change in short-term borrowings
|
(2,228)
|
575
|
|
Additional financial liabilities
|
4,278
|
4,234
|
|
Repayment of financial liabilities
|
(3,547)
|
(3,846)
|
|
Capital element of lease rental payments
|
(301)
|
(342)
|
|
Repurchase of shares
|
(1,510)
|
(1,508)
|
|
Other financing activities (c)
|
(1,105)
|
(694)
|
|
Net cash flow used in continuing financing activities
|
(9,884)
|
(6,829)
|
|
Net cash flow used in discontinued financing
activities
|
3,070
|
(112)
|
|
Total net cash flow used in financing activities
|
(6,814)
|
(6,941)
|
|
Net increase/(decrease) in cash and cash equivalents
|
(1,582)
|
1,953
|
|
Cash and cash equivalents at the beginning of the
period
|
5,950
|
4,045
|
|
Effect of foreign exchange rate changes
|
(498)
|
(48)
|
|
Cash and cash equivalents at the end of the period
|
3,870
|
5,950
|
|
Fourth Quarter
|
Beauty & Wellbeing
|
Personal Care
|
Home Care
|
Foods
|
Total
|
|
Turnover (€ million)
|
|
|
|
|
|
|
2024
|
3,310
|
3,235
|
2,960
|
3,434
|
12,939
|
|
2025
|
3,189
|
3,307
|
2,830
|
3,260
|
12,586
|
|
Change (%)
|
(3.7)
|
2.2
|
(4.4)
|
(5.1)
|
(2.7)
|
|
Full Year
|
Beauty & Wellbeing
|
Personal Care
|
Home Care
|
Foods
|
Total
|
|
Turnover (€ million)
|
|
|
|
|
|
|
2024
|
13,157
|
13,618
|
12,352
|
13,352
|
52,479
|
|
2025
|
12,848
|
13,161
|
11,565
|
12,929
|
50,503
|
|
Change (%)
|
(2.3)
|
(3.4)
|
(6.4)
|
(3.2)
|
(3.8)
|
|
|
|
|
|
|
|
|
Operating profit (€ million)
|
|
|
|
|
|
|
2024
|
1,970
|
2,739
|
1,521
|
2,599
|
8,829
|
|
2025
|
2,077
|
2,700
|
1,512
|
2,748
|
9,037
|
|
Underlying operating profit (€ million)
|
|
|
|
|
|
|
2024
|
2,552
|
3,014
|
1,785
|
2,847
|
10,198
|
|
2025
|
2,471
|
2,973
|
1,718
|
2,922
|
10,084
|
|
Fourth Quarter
|
Asia Pacific Africa
|
The Americas
|
Europe
|
Total
|
|
Turnover (€ million)
|
|
|
|
|
|
2024
|
5,691
|
4,831
|
2,417
|
12,939
|
|
2025
|
5,497
|
4,707
|
2,382
|
12,586
|
|
Change (%)
|
(3.4)
|
(2.6)
|
(1.5)
|
(2.7)
|
|
Full Year
|
Asia Pacific Africa
|
The Americas
|
Europe
|
Total
|
|
Turnover (€ million)
|
|
|
|
|
|
2024
|
23,448
|
19,605
|
9,426
|
52,479
|
|
2025
|
22,42
|
18,622
|
9,454
|
50,503
|
|
Change (%)
|
(4.4)
|
(5.0)
|
0.3
|
(3.8)
|
|
|
Full Year
|
|
|
|
2025
|
2024(a)
|
|
EPS - Basic
|
|
|
|
Net profit attributable to shareholders' equity (€
million)
|
9,469
|
5,744
|
|
Average number of shares (millions of share units)
|
2,184.0
|
2,215.6
|
|
EPS - basic (€)
|
4.33
|
2.59
|
|
|
|
|
|
EPS - Basic from continuing operations
|
|
|
|
Net profit from continuing operations attributable to shareholders'
equity (€ million)
|
5,682
|
5,430
|
|
EPS - Basic from continuing operations (€)
|
2.60
|
2.45
|
|
|
|
|
|
EPS - Basic from discontinued operations
|
|
|
|
Net profit from discontinued operations attributable to
shareholders' equity (€ million)
|
3,787
|
314
|
|
EPS - Basic from discontinued operations (€)
|
1.73
|
0.14
|
|
|
|
|
|
EPS - Diluted
|
|
|
|
Net profit attributable to shareholders' equity (€
million)
|
9,469
|
5,744
|
|
Adjusted average number of shares (millions of share
units)
|
2,195.3
|
2,228.5
|
|
EPS - diluted (€)
|
4.32
|
2.58
|
|
|
|
|
|
EPS - Diluted from continuing operations
|
|
|
|
Net profit from continuing operations attributable to shareholders'
equity (€ million)
|
5,682
|
5,430
|
|
EPS - Diluted from continuing operations (€)
|
2.59
|
2.44
|
|
|
|
|
|
EPS - Diluted from discontinued operations
|
|
|
|
Net profit from discontinued operations attributable to
shareholders' equity (€ million)
|
3,787
|
314
|
|
EPS - Diluted from discontinued operations (€)
|
1.73
|
0.14
|
|
|
Millions
|
|
Number of shares at 31 December 2024 (net of treasury
shares)
|
2,475.6
|
|
Shares repurchased under the share buyback programme
|
(27.8)
|
|
Net movements in shares under incentive schemes
|
4.1
|
|
Impact of share consolidation
|
(272.4)
|
|
Number of shares at 31 December 2025 (net of treasury
shares)
|
2,179.5
|
|
|
€ million
2025
|
|
Fair value of the Ice Cream business distributed
(80.15%)
|
6,752
|
|
Fair value of the retained ownership in TMICC (19.85%)
|
1,672
|
|
Total fair value
|
8,424
|
|
Carrying amount of the net assets and liabilities
distributed/de-recognised, comprised of:
|
|
|
Goodwill
|
(3,322)
|
|
Intangible Assets
|
(729)
|
|
Property, Plant and Equipment
|
(2,234)
|
|
Pension assets
|
(80)
|
|
Inventories
|
(925)
|
|
Net deferred tax assets
|
(302)
|
|
Other non-current assets
|
(10)
|
|
Trade and other current receivables
|
(1,960)
|
|
Cash and cash equivalents
|
(531)
|
|
Current tax assets
|
(43)
|
|
Trade payables and other current liabilities
|
2,797
|
|
Financial liabilities
|
3,179
|
|
Pension liabilities
|
86
|
|
Provisions
|
59
|
|
Total carrying amount of net assets de-recognised
|
(4,015)
|
|
Gain on demerger before exchange movements
|
4,409
|
|
Loss on recycling of currency retranslation on
disposal
|
(1,036)
|
|
Total gain on the demerger after tax
|
3,373
|
|
Total results from discontinued operations (Ice Cream)
|
€ million
2025
|
€ million
2024
|
|
Turnover
|
7,691
|
8,282
|
|
Operating profit
|
677
|
571
|
|
Profit before tax from discontinued operations
|
613
|
498
|
|
Taxation
|
(188)
|
(168)
|
|
Profit after taxation from discontinued operations
|
425
|
330
|
|
Total gain on demerger after tax
|
3,373
|
-
|
|
Profit after taxation on demerger of discontinued
operations
|
3,798
|
330
|
|
Attributable to:
|
|
|
|
Non-controlling interests
|
11
|
16
|
|
Shareholders' equity
|
3,787
|
314
|
|
Earnings per share from discontinued operations
|
1.73
|
0.14
|
|
Diluted earnings per share from discontinued
operations
|
1.73
|
0.14
|
|
Deal completion date
|
Acquired/disposed business
|
|
1
April 2025
|
Acquired
100% of Wild, a U.K. based company known for its natural,
refillable deodorants, lip balms, body washes, and
handwashes.
|
|
1
April 2025
|
Sold
Conimex brand to Paulig Group.
|
|
1
April 2025
|
Acquired
the remaining 20% of Nutraceutical Wellness, Inc. (Nutrafol),
bringing the Group's ownership to 100%.
|
|
21
April 2025
|
HUL
acquired 90.5% of Minimalist, an India based premium actives-led
beauty brand.
|
|
2
September 2025
|
Acquired
98.7% of Dr. Squatch, a U.S. based brand specialized in natural
personal care products.
|
|
€ million
|
Total 2025
|
|
Intangible assets
|
1,109
|
|
Other non-current assets
|
67
|
|
Trade and other receivables
|
66
|
|
Other current assets(a)
|
134
|
|
Non-current liabilities(b)
|
(311)
|
|
Current liabilities
|
(85)
|
|
Net assets acquired
|
980
|
|
Non-controlling interest
|
(30)
|
|
Goodwill(c)
|
784
|
|
Total consideration
|
1,734
|
|
of which:
|
|
|
Cash
consideration paid
|
1,687
|
|
Deferred
consideration
|
47
|
|
€ million
|
2025
|
2024
|
|
Goodwill and intangible assets(a)
|
71
|
1,107
|
|
Other non-current assets
|
27
|
218
|
|
Current assets
|
8
|
700
|
|
Liabilities
|
(1)
|
(683)
|
|
Net assets sold
|
105
|
1,342
|
|
Loss on recycling of currency retranslation on
disposal
|
24
|
545
|
|
Non-controlling interest
|
-
|
(85)
|
|
Profit/(loss) on sale attributable to Unilever
|
(36)
|
(406)
|
|
Consideration
|
93
|
1,396
|
|
Of which:
|
|
|
|
Cash
|
93
|
1,299
|
|
Non-cash
items and deferred consideration
|
-
|
97
|
|
|
31 December 2025
|
31 December 2024
|
||||
|
€ million
|
Current
|
Non-current
|
Total
|
Current
|
Non-current
|
Total
|
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
Cash at bank and in hand
|
2,490
|
-
|
2,490
|
3,241
|
-
|
3,241
|
|
Short-term deposits(a)
|
1,066
|
-
|
1,066
|
2,436
|
-
|
2,436
|
|
Other cash equivalents(b)
|
385
|
-
|
385
|
459
|
-
|
459
|
|
|
3,941
|
-
|
3,941
|
6,136
|
-
|
6,136
|
|
Other financial assets
|
|
|
|
|
|
|
|
Financial assets at amortised cost(c)
|
541
|
368
|
909
|
736
|
526
|
1,262
|
|
Financial assets at fair value through other comprehensive
income(d)
|
-
|
2,216
|
2,216
|
-
|
600
|
600
|
|
Financial assets at fair value through profit or loss:
|
|
|
|
|
|
|
|
Derivatives
|
50
|
140
|
190
|
149
|
68
|
217
|
|
Other(e)
|
530
|
341
|
871
|
445
|
377
|
822
|
|
|
1,121
|
3,065
|
4,186
|
1,330
|
1,571
|
2,901
|
|
Total financial
assets(f)
|
5,062
|
3,065
|
8,127
|
7,466
|
1,571
|
9,037
|
|
|
Fair value
|
Carrying
amount
|
||
|
€ million
|
As
at 31 December 2025
|
As at 31 December 2024
|
As at 31 December 2025
|
As at 31 December 2024
|
|
Financial assets
|
|
|
|
|
|
Cash and cash equivalents
|
3,941
|
6,136
|
3,941
|
6,136
|
|
Financial assets at amortised cost
|
909
|
1,262
|
909
|
1,262
|
|
Financial assets at fair value through other comprehensive
income
|
2,216
|
600
|
2,216
|
600
|
|
Financial assets at fair value through profit and
loss:
|
|
|
|
|
|
Derivatives
|
190
|
217
|
190
|
217
|
|
Other
|
871
|
822
|
871
|
822
|
|
|
8,127
|
9,037
|
8,127
|
9,037
|
|
Financial liabilities
|
|
|
|
|
|
Bank loans and overdrafts
|
(233)
|
(521)
|
(233)
|
(521)
|
|
Bonds and other loans
|
(25,655)
|
(28,037)
|
(26,038)
|
(28,648)
|
|
Lease liabilities
|
(1,326)
|
(1,486)
|
(1,326)
|
(1,486)
|
|
Derivatives
|
(452)
|
(594)
|
(452)
|
(594)
|
|
Other financial liabilities
|
(229)
|
(804)
|
(229)
|
(804)
|
|
|
(27,895)
|
(31,442)
|
(28,278)
|
(32,053)
|
|
|
As at 31 December 2025
|
As at 31 December 2024
|
||||
|
€ million
|
Level 1
|
Level 2
|
Level 3
|
Level 1
|
Level 2
|
Level 3
|
|
Assets at fair value
|
|
|
|
|
|
|
|
Financial assets at fair value through other
comprehensive income
|
1,663
|
4
|
549
|
10
|
4
|
586
|
|
Financial assets at fair value through profit or loss:
|
|
|
|
|
|
|
|
Derivatives(a)
|
-
|
210
|
-
|
-
|
420
|
-
|
|
Other
|
530
|
-
|
341
|
445
|
-
|
377
|
|
Liabilities at fair value
|
|
|
|
|
|
|
|
Derivatives(b)
|
-
|
(503)
|
-
|
-
|
(650)
|
-
|
|
Contingent
consideration
|
-
|
-
|
(46)
|
-
|
-
|
(1)
|
|
Per Unilever PLC ordinary share (traded on the London Stock
Exchange):
|
£0.4052
|
|
Per Unilever PLC ordinary share (traded on Euronext in
Amsterdam):
|
€0.4664
|
|
Per Unilever PLC American Depositary Receipt:
|
US$0.5547
|
|
|
Announcement
Date
|
Ex-dividend Date for Ordinary Shares
|
Ex-dividend Date for ADRs
|
Record Date
|
Last Date for DRIP Election
|
Payment Date
|
|
Q4 2025 Dividend
|
12
February 2026
|
26
February 2026
|
27
February 2026
|
27
February 2026
|
18
March 2026
|
10
April 2026
|
|
Q1 2026 Dividend
|
30
April 2026
|
14
May 2026
|
15
May 2026
|
15
May 2026
|
05
June 2026
|
26
June 2026
|
|
Q2 2026 Dividend
|
28
July 2026
|
06
August 2026
|
07
August 2026
|
07
August 2026
|
27
August 2026
|
18
September 2026
|
|
Q3 2026 Dividend
|
28
October 2026
|
12
November 2026
|
13
November 2026
|
13
November 2026
|
27
November 2026
|
18
December 2026
|
|
UNILEVER PLC
|
|
/S/ M VARSELLONA
|
|
|
|
|
|
By M VARSELLONA
|
|
CHIEF LEGAL OFFICER AND GROUP SECRETARY
|